Cite
HARVARD Citation
Johnson, C. et al. (n.d.). IL-12 primed CD8+ T-cells possess enhanced persistence and anti-tumor efficacy because of greater IL-7 responsiveness. Journal for immunotherapy of cancer. p. . [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Johnson, C. et al. (n.d.). IL-12 primed CD8+ T-cells possess enhanced persistence and anti-tumor efficacy because of greater IL-7 responsiveness. Journal for immunotherapy of cancer. p. . [Online].